Lupus Nephritis-Pipeline Review, H1 2016
Description: The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. Request a sample of this report @ http://www.orbisresearch.com/contacts/requestsample/144016 .
Global Markets Directâ€™s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directâ€™s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Browse the complete report @ http://www.orbisresearch.com/reports/index/lupus-nephritispipeline-review-h1-2016 .
Companies Mentioned: Astellas Pharma Inc. Beijing Minhai Biotechnology Co., Ltd Beijing Tiantan Biological Products Co., Ltd. China National Pharmaceutical Group Corporation ContraVir Pharmaceuticals, Inc. Epiphany Biosciences, Inc. Foamix Pharmaceuticals Ltd. GeneOne Life Science, Inc. GlaxoSmithKline Plc Green Cross Corporation Merck & Co., Inc. NAL Pharmaceuticals Ltd. ReceptoPharm, Inc. 2
Sinovac Biotech Ltd. TSRL, Inc. Zydus Cadila Healthcare Limited If you have any enquiry before buying a copy of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/144016 .
List of Figures Number of Products under Development for Lupus Nephritis, H1 2016 10 Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Top 10 Targets, H1 2016 37 Number of Products by Stage and Top 10 Targets, H1 2016 37 Number of Products by Top 10 Mechanism of Actions, H1 2016 39 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 39 Contact firstname.lastname@example.org for more information. About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Us: Hector Costello Senior Manager â€“ Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas - 75204, U.S.A. Phone No.: +1 (214) 884-6817; +912064101019 Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research Follow us on Twitter: https://twitter.com/orbisresearch Like us on Facebook: https://www.facebook.com/pages/Orbis-Research/820969017982115 3